Detalhe da pesquisa
1.
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.
BMC Cancer
; 24(1): 641, 2024 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38789924
2.
Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial.
Gastric Cancer
; 26(1): 123-131, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36066725
3.
Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
Lancet Oncol
; 22(1): 85-97, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33357420
4.
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
N Engl J Med
; 372(8): 724-34, 2015 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-25693012
5.
Interaction between differentially methylated regions partitions the imprinted genes Igf2 and H19 into parent-specific chromatin loops.
Nat Genet
; 36(8): 889-93, 2004 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15273689
6.
Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer.
Eur J Cancer
; 178: 70-81, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36410207
7.
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.
Eur J Cancer
; 166: 219-228, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35313167
8.
Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
J Clin Pharmacol
; 59(5): 702-716, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30570763
9.
Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy.
J Clin Oncol
; 35(26): 3030-3038, 2017 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28437161
10.
An association between variants in the IGF2 gene and Beckwith-Wiedemann syndrome: interaction between genotype and epigenotype.
Hum Mol Genet
; 13(2): 247-55, 2004 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-14645199